Dr. Xie Xuanhui founded TVM Capital China in 2012 and later upgraded the brand to ValueSeek Ventures, focusing on incubating original innovations from scratch. He has collaborated with Eli Lilly and its subsidiary Chorus to incubate multiple first-in-class pipelines and achieve major exits. Particularly in cutting-edge fields like CGT, Dr. Xie has used a Hub-Spoke model to start a series of companies covering cancer, autoimmune, infectious, skin, and age-related diseases. In addition, he is dedicated to helping leading domestic companies in niche fields expand internationally through the Newco 2.0 model. Earlier, Dr. Xie also co-founded companies in the bioeconomy sector, including animal vaccines, medical aesthetics, and synthetic biology.